+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

North America Chronic Cough Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Drug Class; Route of Administration; Distribution Channel; and Country

  • ID: 5147234
  • Report
  • August 2020
  • Region: North America
  • 97 pages
  • The Insight Partners
UP TO OFF
until Sep 30th 2021

FEATURED COMPANIES

  • Aurobindo Pharma Ltd
  • Bayer AG
  • Cipla Inc.
  • GlaxoSmithKline plc.
  • Mylan N.V.
  • Novartis AG
The North American Chronic Cough market is projected to reach US$ 3,944.89 million by 2027 from US$ 2,118.42 million in 2019; it is estimated to grow with a CAGR of 8.1% from 2020 to 2027.

The growth of the chronic cough market is primarily attributed to rising incidences of chronic cough, growing product developments to treat chronic cough. More over the rising outbreak of the COVID-19 pandemic has highly affected the countries in the North American region and the chronic cough market in the region.

The developments in the pharmaceutical and biopharmaceutical industry for the drugs that can treat chronic cough are likely to lead the market growth. Additionally, there is a rise in the number of global pharmaceutical companies and several startups across the region are involved in the product development for chronic cough. For instance, in May 2020, BELLUS Health Inc., a biopharmaceutical company, has developed novel therapeutics for the chronic cough and other hypersensitization-related disorders. The company is continuously engaged in product development and has recently conducted a virtual key opinion leader (KOL) meeting to discuss the development regarding chronic cough on 27 May 2020. Specifically, the conference covered the developmental aspects regarding the phase 2 RELIEF trial of BLU-5937 in chronic refractory cough. The company is looking forward to releasing data of clinical trials for RELIEF in June or July 2020t
In 2019, the drug class segment accounted for a larger share of the North American chronic cough market. Its growth is attributed to growing product developments to treat chronic cough. Additionally, rising incidences of chronic cough likely to drive the growth of drug class segment in the North American chronic cough market.

A few major primary and secondary sources for the chronic cough market included in the report are Instrument, US Food and Drug Administration, and Canada Foundation of Innovation.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Aurobindo Pharma Ltd
  • Bayer AG
  • Cipla Inc.
  • GlaxoSmithKline plc.
  • Mylan N.V.
  • Novartis AG
1. Introduction
1.1 Scope of the Study
1.2 Report Guidance
1.3 Market Segmentation
1.3.1 Chronic Cough Market - By Drug Class
1.3.2 Chronic Cough Market - By Route of Administration
1.3.3 Chronic Cough Market - By Distribution Channel
1.3.4 North America Chronic Cough Market - By Country

2. Chronic Cough Market - Key Takeaways

3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. Chronic Cough Market - Market Landscape
4.1 Overview
4.2 PEST Analysis
4.2.1 Expert Opinion

5. Chronic Cough Market - Key Market Dynamics
5.1 Market Drivers
5.1.1 Rising Incidences of Chronic Cough
5.1.2 Growing Product Developments to Treat Chronic Cough
5.2 Market Restraints
5.2.1 Product Recalls
5.3 Market Opportunities
5.3.1 Aging Population is Expected to Drive Demand for Chronic Cough Treatment
5.4 Future Trends
5.4.1 Continuous Trend of Drug Development
5.5 Impact Analysis

6. Chronic Cough Market Analysis - By Drug Class
6.1 Overview
6.2 Chronic Cough Market Revenue Share, by Drug Class (2019 and 2027)
6.3 Antihistamines
6.3.1 Overview
6.3.2 Antihistamines: Chronic Cough Market - Revenue and Forecast to 2027 (US$ Million)
6.4 Corticosteroids
6.4.1 Overview
6.4.2 Corticosteroids: Chronic Cough Market - Revenue and Forecast to 2027 (US$ Million)
6.5 Decongestants
6.5.1 Overview
6.5.2 Decongestants: Chronic Cough Market - Revenue and Forecast to 2027 (US$ Million)
6.6 Combination Drug
6.6.1 Overview
6.6.2 Combination Drug: Chronic Cough Market - Revenue and Forecast to 2027 (US$ Million)
6.7 Antibiotics
6.7.1 Overview
6.7.2 Antibiotics: Chronic Cough Market - Revenue and Forecast to 2027 (US$ Million)
6.8 Acid Blockers
6.8.1 Overview
6.8.2 Acid Blockers: Chronic Cough Market - Revenue and Forecast to 2027 (US$ Million)
6.9 Other Drug Class
6.9.1 Overview
6.9.2 Other Drug Class: Chronic Cough Market - Revenue and Forecast to 2027 (US$ Million)

7. Chronic Cough Market - By Route of Administration
7.1 Overview
7.2 Chronic Cough Market, by Route of Administration, 2019 and 2027 (%)
7.3 Oral
7.3.1 Overview
7.3.2 Oral: Chronic Cough Market - Revenue and Forecast to 2027 (US$ Million)
7.4 Injections
7.4.1 Overview
7.4.2 Injections: Chronic Cough Market - Revenue and Forecast to 2027 (US$ Million)
7.5 Inhalation
7.5.1 Overview
7.5.2 Inhalation: Chronic Cough Market - Revenue and Forecast to 2027 (US$ Million)
7.6 Other Route of Administration
7.6.1 Overview
7.6.2 Other Route of Administration: Chronic Cough Market - Revenue and Forecast to 2027 (US$ Million)

8. Chronic Cough Market - By Distribution Channel
8.1 Overview
8.2 Chronic Cough Market, by Distribution Channel, 2019 and 2027 (%)
8.3 Hospital Pharmacy
8.3.1 Overview
8.3.2 Hospital Pharmacy: Chronic Cough Market - Revenue and Forecast to 2027 (US$ Million)
8.4 Online Pharmacy
8.4.1 Overview
8.4.2 Online Pharmacy: Chronic Cough Market - Revenue and Forecast to 2027 (US$ Million)
8.5 Retail Pharmacy
8.5.1 Overview
8.5.2 Retail Pharmacy: Chronic Cough Market - Revenue and Forecast to 2027 (US$ Million)

9. Chronic Cough Market - Regional Analysis
9.1 North America Chronic Cough Market
9.1.1 Overview
9.1.2 North America: Chronic Cough Market - Revenue and Forecast to 2027 (USD Million)
9.1.3 North America: Chronic Cough Market, by Drug Class, 2018-2027 (USD Million)
9.1.4 North America: Chronic Cough Market, by Route of Administration, 2018-2027 (USD Million)
9.1.5 North America: Chronic Cough Market, by Distribution Channel, 2018-2027 (USD Million)
9.1.6 North America: Chronic Cough Market, by Country, 2019 & 2027 (%)
9.1.7 US: Chronic Cough Market - Revenue and Forecast to 2027 (USD Million)
9.1.7.1 US: Chronic Cough Market - Revenue and Forecast to 2027 (USD Million)
9.1.7.2 US: Chronic Cough Market, by Drug Class, 2018-2027 (USD Million)
9.1.7.3 US: Chronic Cough Market, by Route of Administration, 2018-2027 (USD Million)
9.1.7.4 US: Chronic Cough Market, by Distribution Channel, 2018-2027 (USD Million)
9.1.8 Canada: Chronic Cough Market - Revenue and Forecast to 2027 (USD Million)
9.1.8.1 Canada: Chronic Cough Market - Revenue and Forecast to 2027 (USD Million)
9.1.8.2 Canada: Chronic Cough Market, by Drug Class, 2018-2027 (USD Million)
9.1.8.3 Canada: Chronic Cough Market, by Route of Administration, 2018-2027 (USD Million)
9.1.8.4 Canada: Chronic Cough Market, by Distribution Channel, 2018-2027 (USD Million)
9.1.9 Mexico: Chronic Cough Market - Revenue and Forecast to 2027 (USD Million)
9.1.9.1 Mexico: Chronic Cough Market - Revenue and Forecast to 2027 (USD Million)
9.1.9.2 Mexico: Chronic Cough Market, by Drug Class, 2018-2027 (USD Million)
9.1.9.3 Mexico: Chronic Cough Market, by Route of Administration, 2018-2027 (USD Million)
9.1.9.4 Mexico: Chronic Cough Market, by Distribution Channel, 2018-2027 (USD Million)

10. Impact of COVID-19 Pandemic on North America Chronic cough Market
10.1 Impact Assessment of COVID-19 Pandemic

11. COMPANY PROFILES
11.1 Novartis AG
11.1.1 Key Facts
11.1.2 Business Description
11.1.3 Products and Services
11.1.4 Financial Overview
11.1.5 SWOT Analysis
11.1.6 Key Developments
11.2 TEVA PHARMACEUTICAL INDUSTRIES LTD
11.2.1 Key Facts
11.2.2 Business Description
11.2.3 Products and Services
11.2.4 Financial Overview
11.2.5 SWOT Analysis
11.2.6 Key Developments
11.3 GlaxoSmithKline plc.
11.3.1 Key Facts
11.3.2 Business Description
11.3.3 Products and Services
11.3.4 Financial Overview
11.3.5 SWOT Analysis
11.3.6 Key Developments
11.4 Bayer AG
11.4.1 Key Facts
11.4.2 Business Description
11.4.3 Products and Services
11.4.4 Financial Overview
11.4.5 SWOT Analysis
11.4.6 Key Developments
11.5 MYLAN N.V.
11.5.1 Key Facts
11.5.2 Business Description
11.5.3 Products and Services
11.5.4 Financial Overview
11.5.5 SWOT Analysis
11.5.6 Key Developments
11.6 Amneal Pharmaceuticals, Inc.
11.6.1 Key Facts
11.6.2 Business Description
11.6.3 Products and Services
11.6.4 Financial Overview
11.6.5 SWOT Analysis
11.6.6 Key Developments
11.7 Cipla Inc.
11.7.1 Key Facts
11.7.2 Business Description
11.7.3 Products and Services
11.7.4 Financial Overview
11.7.5 SWOT Analysis
11.7.6 Key Developments
11.8 Reckitt Benckiser Group plc.
11.8.1 Key Facts
11.8.2 Business Description
11.8.3 Products and Services
11.8.4 Financial Overview
11.8.5 SWOT Analysis
11.8.6 Key Developments
11.9 Sun Pharmaceutical Industries Ltd
11.9.1 Key Facts
11.9.2 Business Description
11.9.3 Products and Services
11.9.4 Financial Overview
11.9.5 SWOT Analysis
11.9.6 Key Developments
11.10 Aurobindo Pharma Ltd
11.10.1 Key Facts
11.10.2 Business Description
11.10.3 Products and Services
11.10.4 Financial Overview
11.10.5 SWOT Analysis
11.10.6 Key Developments

12. Appendix
12.1 Glossary of Terms

List of Tables
Table 1. North America Chronic Cough Market, by Drug Class – Revenue and Forecast to 2027 (USD Million)
Table 2. North America Chronic Cough Market, by Route of Administration– Revenue and Forecast to 2027 (USD Million)
Table 3. North America Chronic Cough Market, by Distribution Channel– Revenue and Forecast to 2027 (USD Million)
Table 4. US Chronic Cough Market, by Drug Class – Revenue and Forecast to 2027 (USD Million)
Table 5. US Chronic Cough Market, by Route of Administration– Revenue and Forecast to 2027 (USD Million)
Table 6. US Chronic Cough Market, by Distribution Channel– Revenue and Forecast to 2027 (USD Million)
Table 7. Canada Chronic Cough Market, by Drug Class – Revenue and Forecast to 2027 (USD Million)
Table 8. Canada Chronic Cough Market, by Route of Administration– Revenue and Forecast to 2027 (USD Million)
Table 9. Canada Chronic Cough Market, by Distribution Channel– Revenue and Forecast to 2027 (USD Million)
Table 10. Mexico Chronic Cough Market, by Drug Class – Revenue and Forecast to 2027 (USD Million)
Table 11. Mexico Chronic Cough Market, by Route of Administration– Revenue and Forecast to 2027 (USD Million)
Table 12. Mexico Chronic Cough Market, by Distribution Channel– Revenue and Forecast to 2027 (USD Million)
Table 13. Glossary of Terms, Chronic Cough Market

List of Figures
Figure 1. Chronic Cough Market Segmentation
Figure 2. Chronic Cough Market – By Geography
Figure 3. North America Chronic Cough Market Overview
Figure 4. Combination Drug Segment Held Largest Share of Chronic Cough Market
Figure 5. US to Show Remarkable Growth During Forecast Period
Figure 6. PEST Analysis
Figure 7. Expert Opinion
Figure 8. Chronic Cough Market Impact Analysis of Drivers and Restraints
Figure 9. Chronic Cough Market Revenue Share, by Drug Class (2019 and 2027)
Figure 10. Antihistamines: Chronic Cough Market – Revenue and Forecast to 2027 (US$ Million)
Figure 11. Corticosteroids: Chronic Cough Market – Revenue and Forecast to 2027 (US$ Million)
Figure 12. Decongestants: Chronic Cough Market – Revenue and Forecast to 2027 (US$ Million)
Figure 13. Combination Drug: Chronic Cough Market – Revenue and Forecast to 2027 (US$ Million)
Figure 14. Antibiotics: Chronic Cough Market – Revenue and Forecast to 2027 (US$ Million)
Figure 15. Acid Blockers: Chronic Cough Market – Revenue and Forecast to 2027 (US$ Million)
Figure 16. Other Drug Class: Chronic Cough Market – Revenue and Forecast to 2027 (US$ Million)
Figure 17. Chronic Cough Market, by Route of Administration, 2019 and 2027 (%)
Figure 18. Oral: Chronic Cough Market – Revenue and Forecast to 2027 (US$ Million)
Figure 19. Injections: Chronic Cough Market – Revenue and Forecast to 2027 (US$ Million)
Figure 20. Inhalation: Chronic Cough Market – Revenue and Forecast to 2027 (US$ Million)
Figure 21. Other Route of Administration: Chronic Cough Market – Revenue and Forecast to 2027 (US$ Million)
Figure 22. Chronic Cough Market, by Distribution Channel, 2019 and 2027 (%)
Figure 23. Hospital Pharmacy: Chronic Cough Market – Revenue and Forecast to 2027 (US$ Million)
Figure 24. Online Pharmacy: Chronic Cough Market – Revenue and Forecast to 2027 (US$ Million)
Figure 25. Retail Pharmacy: Chronic Cough Market – Revenue and Forecast to 2027 (US$ Million)
Figure 26. North America: Chronic Cough Market, by Key Country – Revenue (2019) (USD Million)
Figure 27. North America Chronic Cough Market Revenue and Forecast to 2027 (USD Million)
Figure 28. North America: Chronic Cough Market, by Country, 2019 & 2027 (%)
Figure 29. US: Chronic Cough Market – Revenue and Forecast to 2027 (USD Million)
Figure 30. Canada: Chronic Cough Market – Revenue and Forecast to 2027 (USD Million)
Figure 31. Mexico: Chronic Cough Market – Revenue and Forecast to 2027 (USD Million)
Figure 32. Impact of COVID-19 Pandemic in North American Country Markets
Note: Product cover images may vary from those shown

A selection of companies mentioned in this report includes:

  • Novartis AG
  • Teva Pharmaceutical Industries Ltd
  • GlaxoSmithKline plc.
  • Bayer AG
  • Mylan N.V.
  • Amneal Pharmaceuticals, Inc.
  • Cipla Inc.
  • Reckitt Benckiser Group plc.
  • Sun Pharmaceutical Industries Ltd
  • Aurobindo Pharma Ltd
Note: Product cover images may vary from those shown
Adroll
adroll